VEGFA and cancer: To further optimize this approach, the combination of HIF1α blockers and anti-VEGF therapies further increase immune responses in pre-clinical mouse models (Chen et al., 2015) also decreasing tumor metastasis (Maes et al., 2014) via NOTCH1 mediated intravasation of cancer cells (Sonoshita et al., 2011).